PerkinElmer, Inc. (PKI): Price and Financial Metrics


PerkinElmer, Inc. (PKI)

Today's Latest Price: $124.86 USD

0.65 (-0.52%)

Updated Oct 1 4:03pm

Add PKI to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 140 in Medical - Devices & Equipment

See all "A" rated Strong Buy stocks

PKI Stock Summary

  • PKI has a market capitalization of $14,033,839,903 -- more than approximately 88.05% of US stocks.
  • Perkinelmer Inc's stock had its IPO on January 1, 1986, making it an older stock than 92.88% of US equities in our set.
  • The price/operating cash flow metric for Perkinelmer Inc is higher than 86.02% of stocks in our set with a positive cash flow.
  • Stocks that are quantitatively similar to PKI, based on their financial statements, market capitalization, and price volatility, are MYL, WAB, HUN, XYL, and HOLX.
  • PKI's SEC filings can be seen here. And to visit Perkinelmer Inc's official web site, go to www.perkinelmer.com.
PKI Daily Price Range
PKI 52-Week Price Range

PKI Stock Price Chart Technical Analysis Charts


PKI Price/Volume Stats

Current price $124.86 52-week high $128.98
Prev. close $125.51 52-week low $62.91
Day low $123.66 Volume 1,149,598
Day high $128.98 Avg. volume 892,553
50-day MA $118.14 Dividend yield 0.22%
200-day MA $98.54 Market Cap 13.96B

PerkinElmer, Inc. (PKI) Company Bio


PerkinElmer Inc. provides products, services, and solutions to the diagnostics, research, environmental, industrial, and laboratory services markets worldwide. The company operates through two segments, Human Health and Environmental Health. The company was founded in 1931 and is based in Waltham, Massachusetts.

PKI Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$124.86$57.19 -54%

We started the process of determining a valid price forecast for Perkinelmer Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Perkinelmer Inc ranked in the 27th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. As for the metrics that stood out in our discounted cash flow analysis of Perkinelmer Inc, consider:

  • The company's debt burden, as measured by earnings divided by interest payments, is 4.01 -- which is good for besting 53.12% of its peer stocks (US stocks in the Healthcare sector with positive cash flow).
  • 87% of the company's capital comes from equity, which is greater than 71.92% of stocks in our cash flow based forecasting set.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-55%
1%-55%
2%-54%
3%-54%
4%-54%
5%-53%

RMD, ZTS, CPIX, XRAY, and IONS can be thought of as valuation peers to PKI, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.


PKI Latest News Stream


Event/Time News Detail
Loading, please wait...

PKI Latest Social Stream


Loading social stream, please wait...

View Full PKI Social Stream

Latest PKI News From Around the Web

Below are the latest news stories about Perkinelmer Inc that investors may wish to consider to help them evaluate PKI as an investment opportunity.

Gene Expression Market Reflect a Holistic Expansion With Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd., PerkinElmer, Bio-Rad Laboratories, OriGene Technologies, Illumina, Inc., QIAGEN

A report by The Insight Partner's on the Gene Expression Market discusses the growth of the market in great detail. It discusses thoroughly all factors promoting and deterring the market. The report also focuses on the competitive dynamics in the

OpenPR | September 29, 2020

COVID-19 Creates A Windfall For PerkinElmer, And Some Of The Benefits May Linger

It may be indelicate to talk about beneficiaries of a deadly global pandemic, but the reality is that COVID-19 has created an unexpected surge in business for many life sciences companies. In the case of PerkinElmer (PKI), while the recent demand for real-time PCR workstations and kits, liquid handling systems,...

Stephen Simpson, CFA on Seeking Alpha | September 28, 2020

PerkinElmer launches Solus Listeria monocytogenes ELISA assay

PerkinElmer, Inc. has launched the PerkinElmer Solus Listeria monocytogenes ELISA Assay.

Dairy Reporter | September 22, 2020

PerkinElmer Launches DA 7350™ Instrument and Cloud-Based Software for Quality Control in Food Production

WALTHAM, Mass.--(BUSINESS WIRE)--Today PerkinElmer introduces the DA 7350 instrument and software providing continuous quality control testing for food manufacturing processes.

Business Wire | September 15, 2020

Needham upgrade lifts PerkinElmer; shares up 4%

Needham has upgraded PerkinElmer ([[PKI]] +4.0%) to Buy from Hold with a $139 price target (17% upside), also adding the stock to his Conviction Buy list.The analyst is impressed with the "strong operational performance" of the company's Diagnostics segment as the company reported almost doubled earnings in Q2.The company said...

Seeking Alpha | September 11, 2020

Read More 'PKI' Stories Here

PKI Price Returns

1-mo 4.58%
3-mo N/A
6-mo 75.63%
1-year 50.08%
3-year 81.70%
5-year 174.72%
YTD 28.87%
2019 24.01%
2018 7.80%
2017 40.99%
2016 -2.12%
2015 23.21%

PKI Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full PKI Dividend History

Continue Researching PKI

Want to see what other sources are saying about Perkinelmer Inc's financials and stock price? Try the links below:

Perkinelmer Inc (PKI) Stock Price | Nasdaq
Perkinelmer Inc (PKI) Stock Quote, History and News - Yahoo Finance
Perkinelmer Inc (PKI) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7721 seconds.